AIMS: Given the relevance of degenerative joint diseases in our society, the development of a novel pharmacologic intervention is a critically important public health goal. Recently, oleocanthal, a polyphenolic natural compound from extra virgin olive oil, has emerged as a potential therapeutic weapon for the treatment of inflammatory degenerative diseases. The goal of this study was to further evaluate the anti-inflammatory activity of oleocanthal in murine macrophages J774 and murine chondrocytes ATDC5 with a particular focus on the inhibition of gene expression of pro-inflammatory factors such as MIP-1α and IL-6. MAIN METHODS: ATDC5 murine chondrogenic cells and murine macrophages J774 were used. J774 macrophages were tested with different doses of oleocanthal and cell viability was evaluated using the MTT assay. Western blot analysis was carried on in J774 cells using anti NOS2 antibody. Nitrite accumulation was determined in culture supernatant using the Griess reaction. MIP-1α and IL-6 mRNA levels were determined using SYBR Green-based quantitative RT-PCR. MIP-1α and IL-6 protein levels were evaluated using specific ELISA assay. Several cytokines, involved in the inflammatory response, were also tested by BioPlex assay. KEY FINDINGS: First, oleocanthal inhibits LPS-induced NO production in J774 macrophages, without affecting cell viability. Moreover, it inhibits MIP-1α and IL-6 mRNA expression, as well as protein synthesis, in both ATDC5 chondrocytes and J774 macrophages. Oleocanthal also inhibits IL-1β, TNF-α and GM-CSF protein synthesis from LPS-stimulated macrophages. SIGNIFICANCE: Our data confirm a clear potent role of oleocanthal as anti-inflammatory therapeutic agent for future treatment of arthritis or other inflammatory diseases.
AIMS: Given the relevance of degenerative joint diseases in our society, the development of a novel pharmacologic intervention is a critically important public health goal. Recently, oleocanthal, a polyphenolic natural compound from extra virgin olive oil, has emerged as a potential therapeutic weapon for the treatment of inflammatory degenerative diseases. The goal of this study was to further evaluate the anti-inflammatory activity of oleocanthal in murine macrophages J774 and murine chondrocytes ATDC5 with a particular focus on the inhibition of gene expression of pro-inflammatory factors such as MIP-1α and IL-6. MAIN METHODS: ATDC5 murine chondrogenic cells and murine macrophages J774 were used. J774 macrophages were tested with different doses of oleocanthal and cell viability was evaluated using the MTT assay. Western blot analysis was carried on in J774 cells using anti NOS2 antibody. Nitrite accumulation was determined in culture supernatant using the Griess reaction. MIP-1α and IL-6 mRNA levels were determined using SYBR Green-based quantitative RT-PCR. MIP-1α and IL-6 protein levels were evaluated using specific ELISA assay. Several cytokines, involved in the inflammatory response, were also tested by BioPlex assay. KEY FINDINGS: First, oleocanthal inhibits LPS-induced NO production in J774 macrophages, without affecting cell viability. Moreover, it inhibits MIP-1α and IL-6 mRNA expression, as well as protein synthesis, in both ATDC5 chondrocytes and J774 macrophages. Oleocanthal also inhibits IL-1β, TNF-α and GM-CSF protein synthesis from LPS-stimulated macrophages. SIGNIFICANCE: Our data confirm a clear potent role of oleocanthal as anti-inflammatory therapeutic agent for future treatment of arthritis or other inflammatory diseases.
Authors: Nehad M Ayoub; Abu Bakar Siddique; Hassan Y Ebrahim; Mohamed M Mohyeldin; Khalid A El Sayed Journal: Eur J Pharmacol Date: 2017-06-15 Impact factor: 4.432
Authors: Yazan S Batarseh; Loqman A Mohamed; Sweilem B Al Rihani; Youssef M Mousa; Abu Bakar Siddique; Khalid A El Sayed; Amal Kaddoumi Journal: Neuroscience Date: 2017-04-07 Impact factor: 3.590
Authors: Mohamed R Akl; Nehad M Ayoub; Mohamed M Mohyeldin; Belnaser A Busnena; Ahmed I Foudah; Yong-Yu Liu; Khalid A Ei Sayed Journal: PLoS One Date: 2014-05-21 Impact factor: 3.240
Authors: Oselys Rodriguez Justo; Patricia Ucelli Simioni; Dirce Lima Gabriel; Wirla Maria da Silva Cunha Tamashiro; Paulo de Tarso Vieira Rosa; Ângela Maria Moraes Journal: BMC Complement Altern Med Date: 2015-10-29 Impact factor: 3.659
Authors: Afsana Tajmim; Areli K Cuevas-Ocampo; Abu Bakar Siddique; Mohammed H Qusa; Judy Ann King; Khaldoun S Abdelwahed; Jafrin Jobayer Sonju; Khalid A El Sayed Journal: Nutrients Date: 2021-05-18 Impact factor: 5.717